Skip to content

Study · Observational study · 2021

15 results

Semaglutide Once-Weekly Persistence and Adherence Versus Other GLP-1 RAs in Patients with Type 2 Diabetes in a US Real-World Setting.

Uzoigwe C, Liang Y, Whitmire S, Paprocki Y

Diabetes therapy : research, treatment and education of diabetes and related disorders10 Apr 2021Cited by 57 (Europe PMC)

PMID33837922 (opens in a new tab)PMCIDPMC8099966 (opens in a new tab)DOI10.1007/s13300-021-01053-7 (opens in a new tab)PepBankPUB-33837922
Read at sourcePubMedAsk about this study
Jump to 15 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study15

15 results from studies that gave the peptide. 15 results from people.

  1. 01HumanObservational studyOther

    In patients with type 2 diabetes, semaglutide was linked to higher treatment persistence than dulaglutide.

    In plain wordsIn patients with diabetes, semaglutide was linked to more patients continuing treatment than dulaglutide.

    Peptide
    Semaglutide
    Outcome
    IncreaseTreatment persistence versus dulaglutide
    Study

    n: not reported in source

    Comparator
    Dulaglutide
    Outcome group
    Treatment adherence and retention · Pharmacology
    Studied dose
    Dose not stated · 360 daysAs given in this study (human).

    Measurements

    Persistence
    67%
    semaglutide
    Persistence
    56%
    dulaglutide

    Source sentences

    Summary
    Persistence at 360 days was significantly higher for semaglutide QW (67.0%) versus dulaglutide (56.0%), liraglutide (40.4%), and exenatide QW (35.5%); p < 0.001 for all comparisons.
    1 context sentence
    Summary · context
    This retrospective, database study used Optum's de-identified Clinformatics® Data Mart Database to identify glucagon-like peptide 1 receptor agonist (GLP-1 RA) treatment-naïve adult patients with type 2 diabetes (T2D)
  2. 02HumanObservational studyOther

    In patients with type 2 diabetes, dulaglutide was linked to lower treatment persistence than semaglutide.

    In plain wordsIn patients with diabetes, dulaglutide was linked to fewer patients continuing treatment than semaglutide.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    DecreaseTreatment persistence
    Study

    n: not reported in source

    Comparator
    Semaglutide
    Outcome group
    Treatment adherence and retention · Pharmacology
    Studied dose
    Dose not stated · 360 daysAs given in this study (human).

    Measurements

    Persistence
    56%
    dulaglutide
    Persistence
    67%
    semaglutide

    Source sentences

    Summary
    Persistence at 360 days was significantly higher for semaglutide QW (67.0%) versus dulaglutide (56.0%), liraglutide (40.4%), and exenatide QW (35.5%); p < 0.001 for all comparisons.
    1 context sentence
    Summary · context
    This retrospective, database study used Optum's de-identified Clinformatics® Data Mart Database to identify glucagon-like peptide 1 receptor agonist (GLP-1 RA) treatment-naïve adult patients with type 2 diabetes (T2D)
  3. 03HumanObservational studyOther

    In patients with type 2 diabetes, semaglutide was linked to higher treatment persistence than liraglutide.

    In plain wordsIn patients with diabetes, semaglutide was linked to more patients continuing treatment than liraglutide.

    Peptide
    Semaglutide
    Outcome
    IncreaseTreatment persistence versus liraglutide
    Study

    n: not reported in source

    Comparator
    Liraglutide
    Outcome group
    Treatment adherence and retention · Pharmacology
    Studied dose
    Dose not stated · 360 daysAs given in this study (human).

    Measurements

    Persistence
    67%
    semaglutide
    Persistence
    40.4%
    liraglutide

    Source sentences

    Summary
    Persistence at 360 days was significantly higher for semaglutide QW (67.0%) versus dulaglutide (56.0%), liraglutide (40.4%), and exenatide QW (35.5%); p < 0.001 for all comparisons.
    1 context sentence
    Summary · context
    This retrospective, database study used Optum's de-identified Clinformatics® Data Mart Database to identify glucagon-like peptide 1 receptor agonist (GLP-1 RA) treatment-naïve adult patients with type 2 diabetes (T2D)
  4. 04HumanObservational studyOther

    In patients with type 2 diabetes, liraglutide was linked to lower treatment persistence than semaglutide.

    In plain wordsIn patients with diabetes, liraglutide was linked to fewer patients continuing treatment than semaglutide.

    Peptide
    Liraglutide
    Outcome
    DecreaseTreatment persistence
    Study

    n: not reported in source

    Comparator
    Semaglutide
    Outcome group
    Treatment adherence and retention · Pharmacology
    Studied dose
    Dose not stated · 360 daysAs given in this study (human).

    Measurements

    Persistence
    40.4%
    liraglutide
    Persistence
    67%
    semaglutide

    Source sentences

    Summary
    Persistence at 360 days was significantly higher for semaglutide QW (67.0%) versus dulaglutide (56.0%), liraglutide (40.4%), and exenatide QW (35.5%); p < 0.001 for all comparisons.
    1 context sentence
    Summary · context
    This retrospective, database study used Optum's de-identified Clinformatics® Data Mart Database to identify glucagon-like peptide 1 receptor agonist (GLP-1 RA) treatment-naïve adult patients with type 2 diabetes (T2D)
  5. 05HumanObservational studyOther

    In patients with type 2 diabetes, semaglutide was linked to higher treatment persistence than once-weekly exenatide.

    In plain wordsIn patients with diabetes, semaglutide was linked to more patients continuing treatment than once-weekly exenatide.

    Peptide
    Semaglutide
    Outcome
    IncreaseTreatment persistence versus exenatide
    Study

    n: not reported in source

    Comparator
    Exenatide once weekly
    Outcome group
    Treatment adherence and retention · Pharmacology
    Studied dose
    Dose not stated · 360 daysAs given in this study (human).

    Measurements

    Persistence
    67%
    semaglutide
    Persistence
    35.5%
    exenatide

    Source sentences

    Summary
    Persistence at 360 days was significantly higher for semaglutide QW (67.0%) versus dulaglutide (56.0%), liraglutide (40.4%), and exenatide QW (35.5%); p < 0.001 for all comparisons.
    1 context sentence
    Summary · context
    This retrospective, database study used Optum's de-identified Clinformatics® Data Mart Database to identify glucagon-like peptide 1 receptor agonist (GLP-1 RA) treatment-naïve adult patients with type 2 diabetes (T2D)
  6. 06HumanObservational studyOther

    In patients with type 2 diabetes, dulaglutide was linked to higher discontinuation rates than semaglutide.

    In plain wordsIn patients with diabetes, dulaglutide was linked to more treatment discontinuation than semaglutide.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    IncreaseTreatment discontinuation
    Study

    n: not reported in source

    Comparator
    Semaglutide
    Outcome group
    Treatment adherence and retention · Pharmacology
    Studied dose
    Dose not stated

    Measurements

    Discontinuation hazard ratio
    1.22 ratio
    dulaglutide versus semaglutide

    Source sentences

    Summary
    Compared with semaglutide QW, the discontinuation rate was significantly higher for dulaglutide (hazard ratio [HR] 1.22; 95% confidence interval [CI] 1.13, 1.32; p < 0.001), liraglutide (HR 1.80; 95% CI 1.66, 1.95; p < 0.001), and exenatide QW (HR 2.12; 95% CI 1.96, 2.30; p < 0.001).
    1 context sentence
    Summary · context
    This retrospective, database study used Optum's de-identified Clinformatics® Data Mart Database to identify glucagon-like peptide 1 receptor agonist (GLP-1 RA) treatment-naïve adult patients with type 2 diabetes (T2D)
  7. 07HumanObservational studyOther

    In patients with type 2 diabetes, liraglutide was linked to higher discontinuation rates than semaglutide.

    In plain wordsIn patients with diabetes, liraglutide was linked to more treatment discontinuation than semaglutide.

    Peptide
    Liraglutide
    Outcome
    IncreaseTreatment discontinuation
    Study

    n: not reported in source

    Comparator
    Semaglutide
    Outcome group
    Treatment adherence and retention · Pharmacology
    Studied dose
    Dose not stated

    Measurements

    Discontinuation hazard ratio
    1.8 ratio
    liraglutide versus semaglutide

    Source sentences

    Summary
    Compared with semaglutide QW, the discontinuation rate was significantly higher for dulaglutide (hazard ratio [HR] 1.22; 95% confidence interval [CI] 1.13, 1.32; p < 0.001), liraglutide (HR 1.80; 95% CI 1.66, 1.95; p < 0.001), and exenatide QW (HR 2.12; 95% CI 1.96, 2.30; p < 0.001).
    1 context sentence
    Summary · context
    This retrospective, database study used Optum's de-identified Clinformatics® Data Mart Database to identify glucagon-like peptide 1 receptor agonist (GLP-1 RA) treatment-naïve adult patients with type 2 diabetes (T2D)
  8. 08HumanObservational studyOther

    In patients with type 2 diabetes, semaglutide was linked to lower discontinuation rates than dulaglutide.

    In plain wordsIn patients with diabetes, semaglutide was linked to less treatment discontinuation than dulaglutide.

    Peptide
    Semaglutide
    Outcome
    DecreaseDiscontinuation versus dulaglutide
    Study

    n: not reported in source

    Comparator
    Dulaglutide
    Outcome group
    Treatment adherence and retention · Pharmacology
    Studied dose
    Dose not stated

    Measurements

    Discontinuation hazard ratio
    1.22 ratio
    dulaglutide versus semaglutide

    Source sentences

    Summary
    Compared with semaglutide QW, the discontinuation rate was significantly higher for dulaglutide (hazard ratio [HR] 1.22; 95% confidence interval [CI] 1.13, 1.32; p < 0.001), liraglutide (HR 1.80; 95% CI 1.66, 1.95; p < 0.001), and exenatide QW (HR 2.12; 95% CI 1.96, 2.30; p < 0.001).
    1 context sentence
    Summary · context
    This retrospective, database study used Optum's de-identified Clinformatics® Data Mart Database to identify glucagon-like peptide 1 receptor agonist (GLP-1 RA) treatment-naïve adult patients with type 2 diabetes (T2D)
  9. 09HumanObservational studyOther

    In patients with type 2 diabetes, semaglutide was linked to lower discontinuation rates than liraglutide.

    In plain wordsIn patients with diabetes, semaglutide was linked to less treatment discontinuation than liraglutide.

    Peptide
    Semaglutide
    Outcome
    DecreaseDiscontinuation versus liraglutide
    Study

    n: not reported in source

    Comparator
    Liraglutide
    Outcome group
    Treatment adherence and retention · Pharmacology
    Studied dose
    Dose not stated

    Measurements

    Discontinuation hazard ratio
    1.8 ratio
    liraglutide versus semaglutide

    Source sentences

    Summary
    Compared with semaglutide QW, the discontinuation rate was significantly higher for dulaglutide (hazard ratio [HR] 1.22; 95% confidence interval [CI] 1.13, 1.32; p < 0.001), liraglutide (HR 1.80; 95% CI 1.66, 1.95; p < 0.001), and exenatide QW (HR 2.12; 95% CI 1.96, 2.30; p < 0.001).
    1 context sentence
    Summary · context
    This retrospective, database study used Optum's de-identified Clinformatics® Data Mart Database to identify glucagon-like peptide 1 receptor agonist (GLP-1 RA) treatment-naïve adult patients with type 2 diabetes (T2D)
  10. 10HumanObservational studyOther

    In patients with type 2 diabetes, semaglutide was linked to lower discontinuation rates than once-weekly exenatide.

    In plain wordsIn patients with diabetes, semaglutide was linked to less treatment discontinuation than once-weekly exenatide.

    Peptide
    Semaglutide
    Outcome
    DecreaseDiscontinuation versus exenatide
    Study

    n: not reported in source

    Comparator
    Exenatide once weekly
    Outcome group
    Treatment adherence and retention · Pharmacology
    Studied dose
    Dose not stated

    Measurements

    Discontinuation hazard ratio
    2.12 ratio
    exenatide QW versus semaglutide

    Source sentences

    Summary
    Compared with semaglutide QW, the discontinuation rate was significantly higher for dulaglutide (hazard ratio [HR] 1.22; 95% confidence interval [CI] 1.13, 1.32; p < 0.001), liraglutide (HR 1.80; 95% CI 1.66, 1.95; p < 0.001), and exenatide QW (HR 2.12; 95% CI 1.96, 2.30; p < 0.001).
    1 context sentence
    Summary · context
    This retrospective, database study used Optum's de-identified Clinformatics® Data Mart Database to identify glucagon-like peptide 1 receptor agonist (GLP-1 RA) treatment-naïve adult patients with type 2 diabetes (T2D)
  11. 11HumanObservational studyOther

    In patients with type 2 diabetes, adherence did not differ significantly between semaglutide and liraglutide.

    In plain wordsIn patients with diabetes, treatment adherence was similar with semaglutide and liraglutide.

    Peptide
    Semaglutide
    Outcome
    No significant changeAdherence versus liraglutide
    Study

    n: not reported in source

    Comparator
    Liraglutide
    Outcome group
    Treatment adherence and retention · Pharmacology
    Studied dose
    Dose not stated · 360 daysAs given in this study (human).

    Measurements

    Adherence
    39.1%
    semaglutide
    Adherence
    30%
    liraglutide

    Source sentences

    Summary
    Adherence to semaglutide QW versus liraglutide at 360 days and to exenatide QW was 39.1% versus 30.0% [p = 0.07] and 27.7% [p = 0.02], respectively.
    1 context sentence
    Summary · context
    This retrospective, database study used Optum's de-identified Clinformatics® Data Mart Database to identify glucagon-like peptide 1 receptor agonist (GLP-1 RA) treatment-naïve adult patients with type 2 diabetes (T2D)
  12. 12HumanObservational studyOther

    In patients with type 2 diabetes, adherence did not differ significantly between liraglutide and semaglutide.

    In plain wordsIn patients with diabetes, treatment adherence was similar with liraglutide and semaglutide.

    Peptide
    Liraglutide
    Outcome
    No significant changeTreatment adherence
    Study

    n: not reported in source

    Comparator
    Semaglutide
    Outcome group
    Treatment adherence and retention · Pharmacology
    Studied dose
    Dose not stated · 360 daysAs given in this study (human).

    Measurements

    Adherence
    30%
    liraglutide
    Adherence
    39.1%
    semaglutide

    Source sentences

    Summary
    Adherence to semaglutide QW versus liraglutide at 360 days and to exenatide QW was 39.1% versus 30.0% [p = 0.07] and 27.7% [p = 0.02], respectively.
    1 context sentence
    Summary · context
    This retrospective, database study used Optum's de-identified Clinformatics® Data Mart Database to identify glucagon-like peptide 1 receptor agonist (GLP-1 RA) treatment-naïve adult patients with type 2 diabetes (T2D)
  13. 13HumanObservational studyOther

    In patients with type 2 diabetes, semaglutide was linked to higher adherence than once-weekly exenatide.

    In plain wordsIn patients with diabetes, semaglutide was linked to better treatment adherence than once-weekly exenatide.

    Peptide
    Semaglutide
    Outcome
    IncreaseAdherence versus exenatide
    Study

    n: not reported in source

    Comparator
    Exenatide once weekly
    Outcome group
    Treatment adherence and retention · Pharmacology
    Studied dose
    Dose not stated · 360 daysAs given in this study (human).

    Measurements

    Adherence
    39.1%
    semaglutide
    Adherence
    27.7%
    exenatide

    Source sentences

    Summary
    Adherence to semaglutide QW versus liraglutide at 360 days and to exenatide QW was 39.1% versus 30.0% [p = 0.07] and 27.7% [p = 0.02], respectively.
    1 context sentence
    Summary · context
    This retrospective, database study used Optum's de-identified Clinformatics® Data Mart Database to identify glucagon-like peptide 1 receptor agonist (GLP-1 RA) treatment-naïve adult patients with type 2 diabetes (T2D)
  14. 14HumanObservational studyOther

    In patients with type 2 diabetes, adherence was numerically higher with dulaglutide than semaglutide, without statistical significance.

    In plain wordsIn patients with diabetes, adherence was numerically higher with dulaglutide than semaglutide, without statistical significance.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    No significant changeTreatment adherence
    Study

    n: not reported in source

    Comparator
    Semaglutide
    Outcome group
    Treatment adherence and retention · Pharmacology
    Studied dose
    Dose not stated · 360 daysAs given in this study (human).

    Measurements

    Adherence
    43.2%
    dulaglutide
    Adherence
    39.1%
    semaglutide

    Source sentences

    Summary
    Adherence to dulaglutide at 360 days was numerically higher than semaglutide QW (43.2% versus 39.1%; p = 0.45) but did not reach statistical significance.
    1 context sentence
    Summary · context
    This retrospective, database study used Optum's de-identified Clinformatics® Data Mart Database to identify glucagon-like peptide 1 receptor agonist (GLP-1 RA) treatment-naïve adult patients with type 2 diabetes (T2D)
  15. 15HumanObservational studyOther

    In patients with type 2 diabetes, adherence was numerically lower with semaglutide than dulaglutide, without statistical significance.

    In plain wordsIn patients with diabetes, adherence was numerically lower with semaglutide than dulaglutide, without statistical significance.

    Peptide
    Semaglutide
    Outcome
    No significant changeAdherence versus dulaglutide
    Study

    n: not reported in source

    Comparator
    Dulaglutide
    Outcome group
    Treatment adherence and retention · Pharmacology
    Studied dose
    Dose not stated · 360 daysAs given in this study (human).

    Measurements

    Adherence
    39.1%
    semaglutide
    Adherence
    43.2%
    dulaglutide

    Source sentences

    Summary
    Adherence to dulaglutide at 360 days was numerically higher than semaglutide QW (43.2% versus 39.1%; p = 0.45) but did not reach statistical significance.
    1 context sentence
    Summary · context
    This retrospective, database study used Optum's de-identified Clinformatics® Data Mart Database to identify glucagon-like peptide 1 receptor agonist (GLP-1 RA) treatment-naïve adult patients with type 2 diabetes (T2D)

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 4Current

    22 Oct 2026, 02:25 UTC

    Study results updated

  2. Versions 2 to 3

    21 Oct 2026, 18:59 UTC

    The same notice was added 2 times, first on 9 Oct 2026, 03:06 UTC. The status did not change between them.

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 03:05 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.